Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 325 of 5804
-
New hope for rare cancer: tarlatamab takes on chemo in phase 3 trial
Disease control Recruiting nowBased on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for tough colorectal cancer: JSKN003 trial launches
Disease control Not yet recruitingThe study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.
Phase: PHASE3 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Weekly shot shows promise in major obesity trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 w…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail targets tough lung cancers
Disease control Recruiting nowThe study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can better staff training in methadone clinics save lives?
Disease control Recruiting nowThe trial of Methadone Patient Access to Collaborative Treatment (MPACT) will establish the impact of the intervention on patient outcomes of methadone treatment retention and in treatment overdose. It will also establish the impact of patient and staff trauma symptoms and clini…
Phase: NA • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a Tampon-Like device catch hidden cancers early?
Diagnosis Not yet recruitingAn exploratory study of early detection and investigation of gynaecological diseases Throughout a woman's life, she may need tests that can feel uncomfortable, such as a smear test or a biopsy taken through the vagina. These tests are important for diagnosing and monitoring wome…
Phase: NA • Sponsor: Ellele Health • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New drug rocbrutinib takes on tough lymphoma in major trial
Disease control Recruiting nowMantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (rev…
Phase: PHASE3 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
AI could predict which stomach cancer patients benefit from Pre-Surgery therapy
Diagnosis Recruiting nowGastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, respons…
Sponsor: Qun Zhao • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New combo could shrink lung tumors before surgery
Disease control Recruiting nowThis trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined wi…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Milk particles may shield preemies from deadly gut condition
Prevention Recruiting nowThe AdVEMPrem study is exploring whether tiny particles called extracellular vesicles (EVs), which are naturally found in human milk, can help protect very premature babies from serious gut problems such as necrotizing enterocolitis (NEC). NEC is a dangerous condition that affect…
Sponsor: Instituto de Investigacion Sanitaria La Fe • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Could cord cell secretions ease arthritis pain?
Disease control CompletedRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, pain, and functional disability. Although conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are the standard treatment…
Phase: PHASE2 • Sponsor: Universitas Sriwijaya • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Loyalty cards could spot cancer months earlier
Diagnosis Recruiting nowCancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectr…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New drug before lung cancer surgery shows promise in early trial
Disease control Not yet recruitingThis is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Vaccine trains immune system to fight HPV-Positive head and neck tumors
Disease control Recruiting nowBVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18. This clinical trial for BVAC-E6E7 consists of two phases: PhaseⅠfocuses on safety and tolerance to determine the maximu…
Phase: PHASE1, PHASE2 • Sponsor: Cellid Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New study tracks Real-World impact of targeted radiation on tough prostate cancers
Disease control Recruiting nowThis non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental CAR T-Cell therapy targets tough leukemias
Disease control Recruiting nowThis Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment (relapsed) or did not respond to treatment (refractor…
Phase: PHASE1, PHASE2 • Sponsor: Gyala Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New radiation drug targets bone cancer cells directly
Disease control Recruiting nowThis is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a coh…
Phase: PHASE1, PHASE2 • Sponsor: Lantheus Medical Imaging • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Second radiation may boost survival in returning throat cancer
Disease control Recruiting nowThis phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma. The study aims to determine whether sequential radiotherapy provides additional survival benefit…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis trial is a multicenter, open-label, Phase II clinical study to explore the efficacy and safety of BL-M07D1 in combination with pembrolizumab in patients with locally advanced or metastatic HER2-overexpressing non-squamous non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC